Advertisement

Prostate Cancer Overdiagnosis and Overtreatment

Analysis of US Mortality and SEER Incidence Trends in the PSA and Pre-PSA Eras
  • Robert A. Stephenson
Chapter
  • 138 Downloads
Part of the Current Clinical Urology book series (CCU)

Abstract

The widespread use of serum prostate-specific antigen (PSA) testing has had profound effects on the diagnosis and treatment of prostate cancers since its introduction in the 1980s (1). As a result of PSA-based improvements in diagnosis and increased levels of diagnostic activity, prostate cancer incidence rates rose abruptly at a rate unprecedented in the history of oncology in the United States. The magnitude of change seen in prostate cancer incidence during the 1990s has not previously been observed in any other cancer (2). Factors that contributed to the unprecedented increase in prostate cancer incidence include the high preclinical prevalence of prostate cancer and the increased detection of prostate cancer using PSA testing resulting from widespread acceptance and use of the PSA test. It appears unlikely that changes in incidence of this magnitude will be seen again for prostate cancer or any other malignancy.

Keywords

Prostate Cancer Mortality Decline Prostate Cancer Diagnosis Prostate Cancer Incidence Prostate Cancer Detection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen: an update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 173.PubMedCrossRefGoogle Scholar
  2. 2.
  3. 3.
    Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999; 150: 848.PubMedCrossRefGoogle Scholar
  4. 4.
    Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble R. The fall in incidence of prostate cancer: on the down side of a PSA induced peak in incidence. Cancer 1996; 77: 1342.PubMedCrossRefGoogle Scholar
  5. 5.
    Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626.PubMedCrossRefGoogle Scholar
  6. 6.
    Stanford JL, Stephenson RA, Coyle LM, et al. Prostate Cancer Trends 1973–1995. NIH Pub. No. 99–4543. SEER Program, National Cancer Institute, Bethesda, MD, 1999.Google Scholar
  7. 7.
    Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from the U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Robert A. Stephenson

There are no affiliations available

Personalised recommendations